Stem cells for the treatment of liver disease

Allen, Katrina J.; Buck, Nicole E.; Williamson, Robert

doi:10.1016/j.trim.2005.09.001

Cited by 22 publications

(11 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whether bone marrow-derived cell therapy can sustain metabolic correction over the long term is unknown. The most important marker of clinical usefulness for cell transplants is the ability to effect liver disease correction [8].…”

Section: Introductionmentioning

confidence: 99%

Correction of copper metabolism is not sustained long term in Wilson’s disease mice post bone marrow transplantation

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Correction of copper metabolism is not sustained long term in Wilson’s disease mice post bone marrow transplantation

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Liver transplantation is the only available therapy for patients with chronic liver failure. Because of the shortage of donated organs, up to 10%-15% of these patients die without receiving an organ in developed countries [1] . In some undeveloped countries the number of deaths on the waiting list might be greater.…”

mentioning

confidence: 99%

Feasibility and safety of autologous bone marrow mononuclear cell transplantation in patients with advanced chronic liver disease

Lyra

Soares²,

Silva³

et al. 2007

WJG

113

View full text Add to dashboard Cite

show abstract

“…The possibility of using SC for stimulation of liver regeneration in CL patients attracts special interest, as a principally new approach to the treatment of this disease [1,4]. Two strategies are now discussed: the use of peripheral stem hemopoietic Response to therapy cells mobilized from the bone marrow by G-CSF and injection of SC isolated from the bone marrow.…”

Section: Resultsmentioning

confidence: 99%

Autologous bone marrow cells in the treatment of cirrhosis of the liver

et al. 2007

View full text Add to dashboard Cite

The data characterizing tolerance and efficiency of autologous bone marrow cells in the treatment of patients with cirrhosis of the liver are presented. Injection of autologous bone marrow cells was not associated with the development of adverse reactions. Cell therapy of patients with compensated cirrhosis arrested asthenic syndrome, reduced cytolysis, increased the level of serum albumin and platelet count. Ultrasonic examination revealed reduction of portal hypertension (the area of the spleen and the portal vein lumen decreased). In patients with decompensated cirrhosis, a positive response presenting as reduction of the disease severity (by 1.9 points) was observed in 48.6% cases. Positive shifts in these patients were associated with a decrease of ALT and AST levels, reduction of laboratory signs of cirrhosis, increase in platelet count, and reduction of the asthenic syndrome. Hence, therapy with autologous bone marrow cells is safe and, according to preliminary results, can be regarded as a new approach to the treatment of patients with cirrhosis of the liver.

show abstract

Stem cells for the treatment of liver disease

Cited by 22 publications

References 112 publications

Correction of copper metabolism is not sustained long term in Wilson’s disease mice post bone marrow transplantation

Correction of copper metabolism is not sustained long term in Wilson’s disease mice post bone marrow transplantation

Feasibility and safety of autologous bone marrow mononuclear cell transplantation in patients with advanced chronic liver disease

Autologous bone marrow cells in the treatment of cirrhosis of the liver

Contact Info

Product

Resources

About